Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature 454, 418-420 (24 July 2008) | doi:10.1038/454418a; Published online 23 July 2008
nature jobs
Postdoctoral Research Fellow
- University of Exeter
- Exeter United Kingdom
Post-Doctoral Fellow
- Stanford University School of Medicine, Department of Cardiothoracic Surgery
- Stanford, California
Alzheimer's disease: Moving towards a vaccine
David M. Holtzman1
Abstract
An agent that clears disease-associated amyloid aggregates from the brains of patients with Alzheimer's disease does not alleviate disease progression. Yet this disappointing news should not rule out such potential therapies.
Alzheimer's disease is the most common cause of dementia. But although there are some drugs that can slightly alleviate its symptoms, there is currently no treatment that can prevent this neurodegenerative disorder, delay its onset or slow its progress.
- David M. Holtzman is in the Department of Neurology and Developmental Biology, Washington University, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Email: holtzman@neuro.wustl.edu
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Can the immune system fight Alzheimer disease?Nature Medicine News and Views (01 Jul 2006)
Neuropathology Alzheimer's in real timeNature News and Views (07 Feb 2008)
See all 10 matches for News And ViewsRESEARCH
Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer diseaseNature Medicine Article (01 Nov 2002)
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case reportNature Medicine Article (01 Apr 2003)
See all 4 matches for Research